August 24, 2016 09:11 AM EDTUpdated June 28, 12:35 PM
Bioregnum
Opinion

BioReg­num: The mob is back. And what's to stop them from go­ing af­ter the en­tire bio­phar­ma in­dus­try?

My­lan to­day is at the cen­ter of the lat­est on­line mael­strom to erupt over drug pric­ing and ac­cess to ther­a­pies. And while it …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times